Certara, DMTC study preventative use of chloroquine for COVID-19

By The Science Advisory Board staff writers

May 7, 2020 -- Certara and DMTC have entered into a research collaboration to evaluate the preventative use of chloroquine in healthcare workers at risk of infection from SARS-CoV-2, the coronavirus strain responsible for COVID-19.

The randomized controlled trial will be led by DMTC, formerly the Defence Materials Technology Centre. The trial will develop mathematical models to understand the viral time course and factors affecting drug exposure and prophylactic response in healthy adult healthcare workers at risk of SARS-CoV-2 infection.

In the study, participants will receive a loading dose followed by weekly doses of chloroquine or placebo to be assessed over a 14-week period.

Certara will provide clinical pharmacology expertise by analyzing the data and conducting exposure-response research to build the model.

Scripps Research expands drug repurposing efforts for COVID-19
Scripps Research has pivoted its drug repurposing collection ReFRAME to find antiviral compounds effective against the novel coronavirus.
Controversy hits Gilead over orphan status for COVID-19 drug
Gilead Sciences has rescinded its request for orphan drug status for an experimental drug for treating COVID-19 just two days after getting approval from...

Copyright © 2020 scienceboard.net


Conferences
Microscopy and Microanalysis Meeting
July 31 - August 4
Portland, Oregon United States
Glasgow International Health Festival
August 24-27
Glasgow, Glasgow City United Kingdom
Pharma Competitive Intelligence Conference and Exhibition
September 21-22
Newark, New Jersey United States
BioProcess International (BPI) Conference
September 27-30
Boston, Massachusetts United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter